Carglumic Acid

Carglumic Acid

SCHEMBL910527

NC(=O)N[C@H](CCC(=O)O)C(=O)O

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CPS1

The experimentally established mechanism targets of Carglumic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 7/20 0.69
NAALAD2 Q9Y3Q0 5/20 0.69
RIMKLA Q8IXN7 1/20 0.69
GNPAT O15228 1/20 0.49
GGH Q92820 1/20 0.48
CA2 P00918 2/20 0.47
CA1 P00915 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Carglumic Acid SCHEMBL910483 1.00 FOLH1 (0.69) FOLH1NAALAD2RIMKLAGNPATGGH
Carglumic Acid SCHEMBL373546 1.00 FOLH1 (0.69) FOLH1NAALAD2RIMKLAGNPATGGH
Carglumic Acid SCHEMBL27983953 1.00 FOLH1 (0.69) FOLH1NAALAD2RIMKLAGNPATGGH
Carglumic Acid SCHEMBL27983952 1.00 FOLH1 (0.69) FOLH1NAALAD2RIMKLAGNPATGGH
Carglumic Acid SCHEMBL27786751 0.98 FOLH1 (0.67) FOLH1NAALAD2RIMKLAGNPATGGH
Carglumic Acid SCHEMBL27772980 0.98 FOLH1 (0.67) FOLH1NAALAD2RIMKLAGNPATGGH
Carglumic Acid SCHEMBL28084488 0.98 FOLH1 (0.67) FOLH1NAALAD2RIMKLAGNPATGGH
Carglumic Acid SCHEMBL27786752 0.98 FOLH1 (0.67) FOLH1NAALAD2RIMKLAGNPATGGH
Carglumic Acid SCHEMBL27873856 0.98 FOLH1 (0.67) FOLH1NAALAD2RIMKLAGNPATGGH
Carglumic Acid SCHEMBL27890153 0.98 FOLH1 (0.67) FOLH1NAALAD2RIMKLAGNPATGGH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116390651-A Methods of modulating gastrointestinal metabolites 帝斯曼知识产权资产管理有限公司 2023-07-04 CN claimed
CN-1376202-A Stereostructure of decarbamylase and use thereof KANEGAFUCHI CHEMICAL IND (JP) 2002-10-23 CN claimed
EP-1209234-A1 STEREOSTRUCTURE OF DECARBAMYLASE AND METHOD OF USING THE SAME Kaneka Corporation (JP) 2002-05-29 EP claimed
EP-4637741-A1 HOMOGENOUSLY SPLITTABLE TABLET COMPOSITIONS COMPRISING CARGLUMIC ACID Santa Farma Ilac Sanayii A.S. (TR) 2025-10-29 EP disclosed
WO-2024136769-A1 HOMOGENOUSLY SPLITTABLE TABLET COMPOSITIONS COMPRISING CARGLUMIC ACID SANTA FARMA ILAC SANAYII A.S. (TR) 2024-06-27 WO disclosed
WO-2024006841-A2 COMPOSITIONS FOR WEIGHT LOSS AND CANCER TREATMENT KNOWLEDGE PHARMACEUTICALS INC. (US) 2024-01-04 WO disclosed
US-20230309502-A1 ANIMAL LITTER COMPOSITIONS AND METHOD OF AMMONIA ABATEMENT CONTROLLED RELEASE TECHNOLOGIES, INC. (US) 2023-10-05 US disclosed
WO-2023158815-A1 ANIMAL LITTER COMPOSITIONS AND METHOD OF AMMONIA ABATMENT CONTROLLED RELEASE TECHNOLOGIES, INC. (US) 2023-08-24 WO disclosed
CN-115315272-A Targeting difunctional degradation agent 耶鲁大学 2022-11-08 CN disclosed
US-20220296584-A1 Membrane Active Molecules KNOWLEDGE PHARMACEUTICALS INC. 2022-09-22 US disclosed
US-20220128556-A1 METHODS OF DIAGNOSING DISEASE 4D Pharma Cork Limited (IE) 2022-04-28 US disclosed
US-7118913-B2 Expression vector containing urea cycle enzyme gene, transformant thereof, and use of transformant for protein over-expression CHUNG-ANG UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) 2006-10-10 US disclosed
EP-1616945-A1 Process for producing D-N-carbamoyl-alpha-amino acids KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 2006-01-18 EP disclosed
EP-1616946-A1 Process for producing D-N-carbamoyl-alpha-amino acids KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 2006-01-18 EP disclosed
US-20050089849-A1 Expression vector containing urea cycle enzyme gene, transformant thereof, and use of transformant for protein over-expression CHUNG-ANG UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) 2005-04-28 US disclosed
CN-1376202-A Stereostructure of decarbamylase and use thereof KANEGAFUCHI CHEMICAL IND (JP) 2002-10-23 CN disclosed
EP-1209234-A1 STEREOSTRUCTURE OF DECARBAMYLASE AND METHOD OF USING THE SAME Kaneka Corporation (JP) 2002-05-29 EP disclosed
WO-2002016626-A1 EXPRESSION VECTOR CONTAINING UREA CYCLE ENZYME GENE, TRANSFORMANT THEREOF, AND USE OF TRANSFORMANT FOR PROTEIN OVER-EXPRESSION INTERBIOGEN, INC. (KR) 2002-02-28 WO disclosed
EP-0801131-A1 PROCESS FOR PRODUCING D-N-CARBAMOYL-$g(a)-AMINO ACID Kanegafuchi Chemical Industry Co., Ltd. (JP) 1997-10-15 EP disclosed
US-4312948-A AGROBACTERIUM CULTURE SNAMPROGETTI S.P.A. (IT) 1982-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220296584-A1 Membrane Active Molecules GABRP, GRIN3A, GRIN2A FOLH1 2512/4885NAALAD2 1575/4885RIMKLA 420/4885
US-20050089849-A1 Expression vector containing urea cycle enzyme gene, transformant thereof, and use of transformant for protein over-expression SLC14A1, OAT, ODC1 FOLH1 709/4885NAALAD2 946/4885RIMKLA 1875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.